可切除NSCLC新辅助免疫疗法联合化疗研究进展
Research Progress of Neoadjuvant Immunotherapy Combined with Chemotherapy for Resectable NSCLC
DOI: 10.12677/acm.2025.152389, PDF,    科研立项经费支持
作者: 朱 培：绍兴文理学院医学院，浙江 绍兴；陈枭栋：宁波大学医学部，浙江 宁波；杨明磊*：宁波市第二医院胸外科，浙江 宁波
关键词: 非小细胞肺癌；新辅助治疗；免疫疗法；化疗；Non-Small Cell Lung Cancer； Neoadjuvant Therapy； Immunotherapy； Chemotherapy
摘要: 肺癌是最常见的肿瘤疾病，其中大约85%的肺癌患者被诊断为非小细胞肺癌(NSCLC)，但经过术后的放化疗效果都不太理想，目前免疫检查点抑制剂(immune checkpoint inhibitors, ICIs)的出现给NSCLC的治疗带来革命性的治疗方案。本文将重点对新辅助免疫疗法联合化疗治疗NSCLC的机制、临床研究，及新辅助治疗后手术效果等方面进行综述。
Abstract: Lung cancer is the most common tumor disease, in which about 85% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC), but after postoperative radiotherapy are less effective, the current emergence of immune checkpoint inhibitors (ICIs) has brought revolutionary therapeutic options to the treatment of NSCLC. In this paper, we will focus on the review of the mechanism, clinical research, and surgical outcome after neoadjuvant immunotherapy combined with chemotherapy for NSCLC.
文章引用：朱培, 陈枭栋, 杨明磊. 可切除NSCLC新辅助免疫疗法联合化疗研究进展[J]. 临床医学进展, 2025, 15(2): 640-646. https://doi.org/10.12677/acm.2025.152389

参考文献

[1] Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., et al. (2019) Durvalumab Plus Platinum–etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial. The Lancet, 394, 1929-1939. [Google Scholar] [CrossRef] [PubMed]
[2] Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S., Carcereny Costa, E., et al. (2019) Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 381, 2020-2031. [Google Scholar] [CrossRef] [PubMed]
[3] Wu, J. and Waxman, D.J. (2018) Immunogenic Chemotherapy: Dose and Schedule Dependence and Combination with Immunotherapy. Cancer Letters, 419, 210-221. [Google Scholar] [CrossRef] [PubMed]
[4] John, J., Ismail, M., Riley, C., Askham, J., Morgan, R., Melcher, A., et al. (2010) Differential Effects of Paclitaxel on Dendritic Cell Function. BMC Immunology, 11, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[5] Ohno, Y., Kitamura, H., Takahashi, N., Ohtake, J., Kaneumi, S., Sumida, K., et al. (2016) IL-6 Down-Regulates HLA Class II Expression and IL-12 Production of Human Dendritic Cells to Impair Activation of Antigen-Specific CD4+ T Cells. Cancer Immunology, Immunotherapy, 65, 193-204. [Google Scholar] [CrossRef] [PubMed]
[6] Mathew, M., Enzler, T., Shu, C.A. and Rizvi, N.A. (2018) Combining Chemotherapy with PD-1 Blockade in NSCLC. Pharmacology & Therapeutics, 186, 130-137. [Google Scholar] [CrossRef] [PubMed]
[7] Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L. and Kroemer, G. (2020) Immunostimulation with Chemotherapy in the Era of Immune Checkpoint Inhibitors. Nature Reviews Clinical Oncology, 17, 725-741. [Google Scholar] [CrossRef] [PubMed]
[8] Provencio, M., Nadal, E., Insa, A., García-Campelo, M.R., Casal-Rubio, J., Dómine, M., et al. (2020) Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Single-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1413-1422. [Google Scholar] [CrossRef] [PubMed]
[9] Bristol Myers Squibb (2022) Opdivo (Nivolumab) Prescribing Information. Massachusetts Medical Society.
https://packageinserts.bms.com/pi/pi_opdivo.pdf
[10] Forde, P.M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M.M., et al. (2022) Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 386, 1973-1985. [Google Scholar] [CrossRef] [PubMed]
[11] Cascone, T., Awad, M.M., Spicer, J.D., He, J., Lu, S., Sepesi, B., et al. (2024) Perioperative Nivolumab in Resectable Lung Cancer. New England Journal of Medicine, 390, 1756-1769. [Google Scholar] [CrossRef] [PubMed]
[12] Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S., Gao, S., et al. (2023) Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. New England Journal of Medicine, 389, 491-503. [Google Scholar] [CrossRef] [PubMed]
[13] Xia, H., Zhang, H., Ruan, Z., Zhang, H., Sun, L., Chen, H., et al. (2024) Neoadjuvant Camrelizumab (an Anti-Pd-1 Antibody) Plus Chemotherapy or Apatinib (a VEGFR-2 Inhibitor) for Initially Unresectable Stage II–III Non-Small-Cell Lung Cancer: A Multicentre, Two-Arm, Phase 2 Exploratory Study. Signal Transduction and Targeted Therapy, 9, Article No. 145. [Google Scholar] [CrossRef] [PubMed]
[14] Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., et al. (2018) A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients with Advanced NSCLC. Journal of Thoracic Oncology, 13, 1138-1145. [Google Scholar] [CrossRef] [PubMed]
[15] Addeo, A., Passaro, A., Malapelle, U., Banna, G.L., Subbiah, V. and Friedlaender, A. (2021) Immunotherapy in Non-Small Cell Lung Cancer Harbouring Driver Mutations. Cancer Treatment Reviews, 96, Article ID: 102179. [Google Scholar] [CrossRef] [PubMed]
[16] Zhang, C., Sun, Y., Yi, D., Jiang, B., Yan, L., Liu, Z., et al. (2024) Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-Mutant NSCLC: Phase 2 Trial Interim Results (NEOTIDE/CTONG2104). Cell Reports Medicine, 5, Article ID: 101615. [Google Scholar] [CrossRef] [PubMed]
[17] Sun, C., Wang, X., Xu, Y., Shao, G., Chen, X., Liu, Y., et al. (2024) Efficiency and Safety of Neoadjuvant PD-1 Inhibitor (Sintilimab) Combined with Chemotherapy in Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: Neo-Pre-IC, a Single-Arm Phase 2 Trial. eClinicalMedicine, 68, Article ID: 102422. [Google Scholar] [CrossRef] [PubMed]
[18] Lu, S., Zhang, W., Wu, L., Wang, W., Zhang, P., Fang, W., et al. (2024) Perioperative Toripalimab Plus Chemotherapy for Patients with Resectable Non–small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA, 331, 201-211. [Google Scholar] [CrossRef] [PubMed]
[19] Lu, S., Wu, L., Zhang, W., Zhang, P., Wang, W., Fang, W., et al. (2023) Perioperative Toripalimab + Platinum-Doublet Chemotherapy vs Chemotherapy in Resectable Stage II/III Non-Small Cell Lung Cancer (NSCLC): Interim Event-Free Survival (EFS) Analysis of the Phase III Neotorch Study. Journal of Clinical Oncology, 41, Article ID: 425126. [Google Scholar] [CrossRef] 
[20] Tao, Y., Li, X., Liu, B., Wang, J., Lv, C., Li, S., et al. (2023) Association of Early Immune-Related Adverse Events with Treatment Efficacy of Neoadjuvant Toripalimab in Resectable Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 13, Article 1135140. [Google Scholar] [CrossRef] [PubMed]
[21] Bott, M.J., Cools-Lartigue, J., Tan, K.S., Dycoco, J., Bains, M.S., Downey, R.J., et al. (2018) Safety and Feasibility of Lung Resection after Immunotherapy for Metastatic or Unresectable Tumors. The Annals of Thoracic Surgery, 106, 178-183. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, W., Liang, Z., Zhao, Y., Li, Y., Chen, T., Li, W., et al. (2024) Efficacy and Safety of Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Adjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Phase 3 Clinical Trials. Frontiers in Immunology, 15, Article 1359302. [Google Scholar] [CrossRef] [PubMed]
[23] Du, C., Chen, Y., Zhou, Y., Zheng, D., Zhao, J., Tang, J., et al. (2023) Neo-adjuvant Chemotherapy Plus Immunotherapy in Resectable N1/N2 NSCLC. BMC Cancer, 23, Article No. 1260. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, Y., Zhang, L., Yan, B., Zeng, Z., Hui, Z., Zhang, R., et al. (2020) Feasibility of Sleeve Lobectomy after Neo-Adjuvant Chemo-Immunotherapy in Non-Small Cell Lung Cancer. Translational Lung Cancer Research, 9, 761-767. [Google Scholar] [CrossRef] [PubMed]
[25] Herbst, R.S., Wang, M. and Chen, L. (2022) When Immunotherapy Meets Surgery in Non-Small Cell Lung Cancer. Cancer Cell, 40, 603-605. [Google Scholar] [CrossRef] [PubMed]
[26] Rhodin, K.E., Rucker, A.J., Ready, N.E., D’Amico, T.A. and Antonia, S.J. (2020) The Immunotherapeutic Landscape in Non–small Cell Lung Cancer and Its Surgical Horizons. The Journal of Thoracic and Cardiovascular Surgery, 159, 1616-1623. [Google Scholar] [CrossRef] [PubMed]
[27] 中华医学会肿瘤学分会. 中华医学会肺癌临床诊疗指南(2024版) [J]. 中华肿瘤杂志, 2024, 46(9): 805-843.
[28] Ulas, E.B. and Bahce, I. (2023) Neoadjuvant Immunochemotherapy in Resectable Non-Small Cell Lung Cancer: The More Cycles, the Better? Translational Lung Cancer Research, 12, 1369-1371. [Google Scholar] [CrossRef] [PubMed]

为你推荐